1200 Pharma
We leverage our breakthrough chemistry, cutting edge computation & data-rich models to accelerate drug discovery.
We leverage our breakthrough chemistry, cutting edge computation & data-rich models to accelerate drug discovery.
1200 Pharma is a biotechnology and pharmaceutical company founded in 2017 by a team of world-renowned chemistry and translational oncology researchers from Caltech and UCLA. The startup's slogan, "We leverage our breakthrough chemistry, cutting edge computation & data-rich models to accelerate drug discovery," reflects its commitment to innovation in drug development. With a focus on leveraging breakthrough medicinal chemistry technology, cutting edge computational design, and data-driven biological research, 1200 Pharma aims to accelerate drug discovery processes and deliver tailored medicines to patients. The company recently received a significant $2.33M Venture Round investment on 15 April 2024, signaling investor confidence in its innovative approach to drug discovery. Despite the absence of specific details about the investors involved in the latest funding round, this investment underscores the potential that 1200 Pharma holds within the biotechnology and pharmaceutical industries. As the startup continues to advance its research and development efforts, its multidisciplinary approach positions it strongly within the evolving landscape of healthcare innovation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $2.33M | - | 15 Apr 2024 | |
| Venture Round | $5.50M | 1 |
|
26 Nov 2019 |
| Seed Round | $6.25M | 1 |
|
22 Nov 2017 |
No recent news or press coverage available for 1200 Pharma.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
